


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Kaisa Health Group Holdings Limited
佳兆業健康集團控股有限公司
(Incorporated in Bermuda with limited liability)
(Stock Code: 876)

INSIDE INFORMATION
RESUMPTION OF TRADING

This announcement is made by Kaisa Health Group Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to (i) the trading halt announcement of the Company dated 5 November 2021 pending the release of an announcement containing inside information of its controlling shareholder, Kaisa Group Holdings Ltd. (Stock Code: 1638) (“**Kaisa Holdings**”), and (ii) the announcements of Kaisa Holdings dated 9 November 2021 and 12 November 2021 in relation to its non-payment with respect to certain financial products and the cessation of the payment of the 2021 interim dividend, respectively.

The Company would like to clarify that it is not involved in or a party to the transactions of Kaisa Holdings noted above. The business operations of the Company are normal. As at the date of this announcement, and based on the information currently available to the Company, on the basis that the Company has not received any financial assistance (whether in the form of loan or financial guarantees) from Kaisa Holdings, the Company considers that any liquidity issues faced by Kaisa Holdings would not have any material adverse impact on the operations of the Company.

At the request of the Company, trading in the shares of the Company on the Stock Exchange was halted with effect from 9:00 a.m. on 5 November 2021 pending the publication of this announcement. Application has been made by the Company for the resumption of trading in the shares of the Company on the Stock Exchange with effect from 9:00 a.m. on 16 November 2021.

Shareholders and investors are reminded to exercise caution when dealing in the securities of the Company.

By Order of the Board
Kaisa Health Group Holdings Limited
Zhang Huagang
Chairman

Hong Kong, 15 November 2021

As at the date of this announcement, the Board comprises six executive Directors, namely Mr. Zhang Huagang (Chairman), Mr. Luo Jun (Co-Vice Chairman), Mr. Wu Tianyu (Co-Vice Chairman), Mr. Kwok Ying Shing, Ms. Kwok Ho Lai and Ms. Kwok Hiu Yan, and three independent non-executive Directors, namely Dr. Liu Yanwen, Dr. Lyu Aiping and Ms. Li Yonglan.